The cost utility of solifenacin in the treatment of overactive bladder
Objectives: Overactive bladder may cause significant discomfort to patients. The standard therapy for overactive bladder includes behavioural therapy and sometimes medication. Recently, a new medication (solifenacin 5 and 10 mg) was developed for treatment of overactive bladder. The objective of this study was to assess the cost utility of solifenacin 5 and 10 mg for overactive bladder. Methods: We developed a Markov model to estimate the cost per quality adjusted life years (QALY) over a period of 12-months. Model parameters were based on randomized clinical trials for solifenacin 5 and 10 mg. Data on utility scores were taken from the literature. Results: The incremental cost per QALY for solifenacin 5 mg and solifenacin 10 mg compared with placebo were £17,602 and £24,464 respectively. Sensitivity analyses showed that these results were robust to changes of relevant input data. Conclusion: Solifenacin 5 and 10 mg are cost-effective treatments in patients with overactive bladder.
|Keywords||Cost-utility analysis, Markov-model, Muscarinic receptor antagonist, Overactive bladder, Urinary incontinence|
|Persistent URL||dx.doi.org/10.1007/s11255-008-9448-2, hdl.handle.net/1765/25027|
van Hakkaart-van Roijen, L, Verboom, P, Phillips, R, & Al, M.J. (2009). The cost utility of solifenacin in the treatment of overactive bladder. International Urology and Nephrology, 41(2), 293–298. doi:10.1007/s11255-008-9448-2